Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Foiling fungal disease post hematopoietic cell transplant: review of prophylactic strategies

Bone Marrow Transplantation volume 53, pages 123–128 (2018)Cite this article

Subjects

Abstract

Hematopoietic cell transplantation (HCT) offers definitive management for a wide variety of malignant and nonmalignant diseases. Conditioning regimens and therapies used to prevent and treat GvHD are immune suppressive, often increasing the risk of developing fungal disease due to yeasts or molds. Antifungal prophylaxis may be useful in preventing morbidity and mortality during and after HCT. In this article, we review the epidemiology and current literature regarding strategies for prevention of invasive fungal disease (IFD) in the pre-engraftment and post-engraftment settings, and propose future direction for scientific discovery.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Savani BN . How can we improve life expectancy and quality of life in long-term survivors after allogeneic stem cell transplantation? Semin Hematol 49: 1–3.

    Article  PubMed  Google Scholar 

  2. Marr KA, Carter RA, Boeckh M, Martin P, Corey L . Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366.

    Article  CAS  PubMed  Google Scholar 

  3. Bhatti Z, Shaukat A, Almyroudis NG, Segal BH . Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 2006; 162: 1–15.

    Article  PubMed  Google Scholar 

  4. Ballen K, Woo Ahn K, Chen M, Abdel-Azim H, Ahmed I, Aljurf M et al. Infection rates among acute leukemia patients receiving alternative donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2016; 22: 1636–1645.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Cordonnier C, Ribaud P, Herbrecht R, Milpied N, Valteau-Couanet D, Morgan C et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42: 955–963.

    Article  CAS  PubMed  Google Scholar 

  6. Stevens DA . Diagnosis of fungal infections: current status. J Antimicrob Chemother 2002; 49 (Suppl 1): 11–19.

    Article  CAS  PubMed  Google Scholar 

  7. Creger RJ, Weeman KE, Jacobs MR, Morrissey A, Parker P, Fox RM et al. Lack of utility of the lysis-centrifugation blood culture method for detection of fungemia in immunocompromised cancer patients. J Clin Microbiol 1998; 36: 290–293.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F et al. Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654–659.

    Article  CAS  PubMed  Google Scholar 

  9. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME . β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011; 52: 750–770.

    Article  CAS  PubMed  Google Scholar 

  10. Pfeiffer CD, Fine JP, Safdar N . Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42: 1417–1727.

    Article  CAS  PubMed  Google Scholar 

  11. Haynes K, Rogers TR . Retrospective evaluation of a latex agglutination test for diagnosis of invasive aspergillosis in immunocompromised patients. Eur J Clin Microbiol Infect Dis 1994; 13: 670–674.

    Article  CAS  PubMed  Google Scholar 

  12. Zou M, Tang L, Zhao S, Zhao Z, Chen L, Chen P et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS ONE 2012; 7: e43347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Guo Y-L, Chen Y-Q, Wang K, Qin S-M, Wu C, Kong J-L . Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. Chest 2010; 138: 817–824.

    Article  PubMed  Google Scholar 

  14. Alexander BD, Pfaller MA . Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 2006; 43 (Suppl 1): S15–S27.

    Article  CAS  Google Scholar 

  15. D'Haese J, Theunissen K, Vermeulen E, Schoemans H, De Vlieger G, Lammertijn L et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol 2012; 50: 1258–1263.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Morrissey CO, Bardy PG, Slavin MA, Ananda-Rajah MR, Chen SC, Kirsa SW et al. Diagnostic and therapeutic approach to persistent or recurrent fevers of unknown origin in adult stem cell transplantation and haematological malignancy. Intern Med J 2008; 38: 477–495.

    Article  CAS  PubMed  Google Scholar 

  17. Slavin MA, Heath CH, Thursky KA, Morrissey CO, Szer J, Ling LM et al. Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. Intern Med J 2008; 38: 468–476.

    Article  CAS  PubMed  Google Scholar 

  18. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–851.

    Article  CAS  PubMed  Google Scholar 

  19. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N . Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28: 331–340.

    Article  CAS  PubMed  Google Scholar 

  20. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25: 5471–5489.

    Article  CAS  PubMed  Google Scholar 

  21. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I . The changing epidemiology of invasive candidiasis. Cancer 2008; 112: 2493–2499.

    Article  PubMed  Google Scholar 

  22. Post MJ, Lass-Floerl C, Gastl G, Nachbaur D . Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 2007; 9: 189–195.

    Article  CAS  PubMed  Google Scholar 

  23. Marr KA, Carter RA, Crippa F, Wald A, Corey L . Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917.

    Article  PubMed  Google Scholar 

  24. Wingard JR, Hsu J, Hiemenz JW . Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2011; 25: 101–116.

    Google Scholar 

  25. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143–1238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cunha C, Aversa F, Lacerda JF, Busca A, Kurzai O, Grube M et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med 2014; 370: 421–432.

    Article  CAS  PubMed  Google Scholar 

  27. Bochud P-Y, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359: 1766–1777.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Seo KW, Kim DH, Sohn SK, Lee NY, Chang HH, Kim SW et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 1089–1095.

    Article  CAS  PubMed  Google Scholar 

  29. Plantinga TS, van der Velden WJ, Ferwerda B, van Spriel AB, Adema G, Feuth T et al. Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. Clin Infect Dis 2009; 49: 724–732.

    Article  CAS  PubMed  Google Scholar 

  30. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–851.

    Article  CAS  PubMed  Google Scholar 

  31. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N . Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28: 331–340.

    Article  CAS  PubMed  Google Scholar 

  32. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545–1552.

    Article  CAS  PubMed  Google Scholar 

  33. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111–5118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ethier MC, Science M, Beyene J, Briel M, Lehrnbecher T, Sung L . Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials. Br J Cancer 2012; 106: 1626–1637.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56–e93.

    Article  PubMed  Google Scholar 

  36. Offner F, Cordonnier C, Ljungman P, Prentice HG, Engelhard D, De Bacquer D et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998; 26: 1098–1103.

    Article  CAS  PubMed  Google Scholar 

  37. Fukuda T, Boeckh M, Guthrie KA, Mattson DK, Owens S, Wald A et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10: 494–503.

    Article  PubMed  Google Scholar 

  38. Cordonnier C, Rovira M, Maertens J, Cornely OA, Ljungman P, Einsele H . Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients. Haematologica 2011; 96: e9–e10.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Garcia-Vidal C, Upton A, Kirby KA, Marr KA . Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041–1050.

    Article  PubMed  Google Scholar 

  40. Martino R, Pinana JL, Parody R, Valcarcel D, Sureda A, Brunet S et al. Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplant 2009; 44: 749–756.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827–833.

    Article  CAS  PubMed  Google Scholar 

  42. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M . Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 115–121.

    Article  CAS  PubMed  Google Scholar 

  43. Martino R, Subirá M, Rovira M, Solano C, Vázquez L, Sanz GF et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475–482.

    Article  PubMed  Google Scholar 

  44. Grow W, Moreb J, Roque D, Manion K, Leather H, Reddy V et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29: 15–20.

    Article  CAS  PubMed  Google Scholar 

  45. Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016; 14: 882–913.

    Article  CAS  PubMed  Google Scholar 

  46. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger U, Frere P et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3[mdash]2009 Update. Bone Marrow Transplant 2011; 46: 709–718.

    Article  CAS  PubMed  Google Scholar 

  47. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348–359.

    Article  CAS  PubMed  Google Scholar 

  48. El Cheikh J, Castagna L, Wang L, Esterni B, Faucher C, Furst S et al. Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study. Hematol Oncol Stem Cell Ther 2010; 3: 167–173.

    Article  CAS  PubMed  Google Scholar 

  49. El-Cheikh J, Faucher C, Furst S, Duran S, Berger P, Vey N et al. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 301–306.

    Article  CAS  PubMed  Google Scholar 

  50. Chaftari AM, Hachem RY, Ramos E, Kassis C, Campo M, Jiang Y et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. Transplantation 2012; 94: 302–308.

    Article  CAS  PubMed  Google Scholar 

  51. Nihtinen A, Anttila VJ, Ruutu T, Juvonen E, Volin L . Low incidence of invasive aspergillosis in allogeneic stem cell transplant recipients receiving amphotericin B inhalation prophylaxis. Transpl Infect Dis 2012; 14: 24–32.

    Article  CAS  PubMed  Google Scholar 

  52. Morello E, Pagani L, Coser P, Cavattoni I, Cortelazzo S, Casini M et al. Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study. Bone Marrow Transplant 2011; 46: 132–136.

    Article  CAS  PubMed  Google Scholar 

  53. Annaloro C, Olivares C, Usardi P, Onida F, Della Volpe A, Tagliaferri E et al. Retrospective evaluation of amphotericin B deoxycholate toxicity in a single centre series of haematopoietic stem cell transplantation recipients. J Antimicrob Chemother 2009; 63: 625–626.

    Article  CAS  PubMed  Google Scholar 

  54. Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011; 155: 318–327.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Martin T, Sharma M, Damon L, Kaplan L, Guglielmo BJ, Working M et al. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2010; 12: 45–50.

    Article  CAS  PubMed  Google Scholar 

  56. Torres A, Serrano J, Rojas R, Martin V, Martin C, Tabares S et al. Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia. Eur J Haematol 2010; 84: 271–273.

    Article  CAS  PubMed  Google Scholar 

  57. Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G et al. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant 2010; 45: 662–667.

    Article  CAS  PubMed  Google Scholar 

  58. Takagi S, Araoka H, Uchida N, Uchida Y, Kaji D, Ota H et al. A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning. Int J Hematol 2014; 99: 652–658.

    Article  CAS  PubMed  Google Scholar 

  59. Vfend (voriconazole) [prescribing information]. Pfizer: New York, NY; February 2015.

  60. Mohr J, Johnson M, Cooper T, Lewis JS, Ostrosky-Zeichner L . Current options in antifungal pharmacotherapy. Pharmacotherapy 2008; 28: 614–645.

    Article  CAS  PubMed  Google Scholar 

  61. Jung DS, Tverdek FP, Kontoyiannis DP . Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother 2014; 58: 6993–6995.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Winston DJ, Bartoni K, Territo MC, Schiller GJ . Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011; 17: 507–515.

    Article  CAS  PubMed  Google Scholar 

  63. Schlemmer F, Lagrange-Xelot M, Lacroix C, de La Tour R, Socie G, Molina JM . Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 42: 551–552.

    Article  CAS  PubMed  Google Scholar 

  64. Mousset S, Bug G, Heinz WJ, Tintelnot K, Rickerts V . Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation. Transpl Infect Dis 2010; 12: 261–264.

    Article  CAS  PubMed  Google Scholar 

  65. Kim T, Jancel T, Kumar P, Freeman AF . Drug–drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring. J Clin Pharm Ther 2015; 40: 609–611.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387: 760–769.

    Article  CAS  Google Scholar 

  67. Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson Iii GR et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 2016; 16: 828–837.

    Article  CAS  PubMed  Google Scholar 

  68. Hiemenz JW, Raad II, Maertens JA, Hachem RY, Saah AJ, Sable CA et al. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis 2010; 29: 1387–1394.

    Article  CAS  PubMed  Google Scholar 

  69. Hiramatsu Y, Maeda Y, Fujii N, Saito T, Nawa Y, Hara M et al. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol 2008; 88: 588–595.

    Article  CAS  PubMed  Google Scholar 

  70. Park HJ, Park M, Han M, Nam BH, Koh KN, Im HJ et al. Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant 2014; 49: 1212–1216.

    Article  CAS  PubMed  Google Scholar 

  71. van Burik J-AH, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407–1416.

    Article  CAS  PubMed  Google Scholar 

  72. Schonfeld W, Wang Cheng J, Tong KB, Seifeldin R . Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation. Clin Ther 2008; 30: 964–973.

    Article  CAS  PubMed  Google Scholar 

  73. Sohn HS, Lee TJ, Kim J, Kim D . Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. Clin Ther 2009; 31: 1105–1115 discussion 1066-8.

    Article  PubMed  Google Scholar 

  74. Pang KA, Godet C, Fekkar A, Scholler J, Nivoix Y, Letscher-Bru V et al. Breakthrough invasive mould infections in patients treated with caspofungin. J Infect 2012; 64: 424–429.

    Article  PubMed  Google Scholar 

  75. Ami RB, Lewis RE, Kontoyiannis DP . Immunopharmacology of modern antifungals. Clin Infect Dis 2008; 47: 226–235.

    Article  CAS  Google Scholar 

  76. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545–1552.

    Article  CAS  PubMed  Google Scholar 

  77. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers MED et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055–2061.

    CAS  PubMed  Google Scholar 

  78. Trifilio S, Verma A, Mehta J . Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 2004; 33: 735–739.

    Article  CAS  PubMed  Google Scholar 

  79. Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94: 113–122.

    Article  PubMed  Google Scholar 

  80. Slade M, Goldsmith S, Romee R et al. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transpl Infect Dis. 2017; 19: e12629 https://doi.org/10.1111/tid.12629.

    Article  CAS  Google Scholar 

  81. Crocchiolo R, Bramanti S, Vai A, Sarina B, Mineri R, Casari E et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis 2015; 17: 242–249.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Aversa F, Prezioso L, Manfra I, Galaverna F, Spolzino A, Monti A . Immunity to infections after haploidentical hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis 2016; 8: e2016057.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013; 19: 117–122.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    S M Rubinstein

  2. Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN, USA

    K A Culos

  3. Division of Hematology/Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    B Savani

  4. Division of Infectious Diseases, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    G Satyanarayana

Authors
  1. S M Rubinstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K A Culos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Savani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Satyanarayana
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Satyanarayana.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rubinstein, S., Culos, K., Savani, B. et al. Foiling fungal disease post hematopoietic cell transplant: review of prophylactic strategies. Bone Marrow Transplant 53, 123–128 (2018). https://doi.org/10.1038/bmt.2017.222

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.222

Search

Advanced search

Quick links